Advancing Cardiac Surgery Through Strategic Innovation at the University of Szeged
The field of cardiac surgery continues to evolve rapidly, with institutions worldwide competing to bring the most effective and durable treatment options to patients. Among these institutions, the University of Szeged in Hungary has recently distinguished itself by achieving a significant milestone in heart valve innovation. A surgical team at the university’s Albert Szent-Györgyi Clinical Center became the first in Europe—and only the third globally—to implant an innovative vascular graft incorporating a biological heart valve in a novel anatomical position.
This achievement represents more than a procedural success. It demonstrates how clinical innovation, when combined with regulatory agility and institutional support, can dramatically improve patient outcomes. For medical professionals and healthcare systems that monitor emerging cardiac surgery techniques, the University of Szeged’s approach offers valuable insights into accelerating the adoption of advanced medical technologies.
Schedule a free consultation to learn more about innovative cardiac treatment options and how they might apply to specific patient cases.
Understanding the Innovative Heart Valve Graft Technology
The vascular graft used in these procedures originated from one of the world’s oldest heart valve manufacturers, based in California. What sets this device apart from conventional solutions is its integrated design: the biological heart valve and synthetic vascular graft arrive preassembled, eliminating the need for surgeons to suture the components together during the operation. This streamlined approach reduces surgical complexity and potentially improves procedural outcomes.
Biological Valve Construction and Preservation
The biological component of the graft is constructed from bovine pericardial tissue and undergoes a specialized preservation process. This treatment is specifically designed to achieve two critical objectives: minimizing the local inflammatory response and significantly reducing calcium buildup. In conventional biological valves, calcification remains a primary factor limiting longevity. By addressing this challenge at the manufacturing level, the new graft is expected to function effectively for a considerably longer period than traditional alternatives.
Anatomical Design Features
Dr. Sándor Varga, Senior Assistant Professor at the Department of Cardiac Surgery, highlighted a particularly important design characteristic: the graft closely replicates the natural anatomy of blood vessels, including the valve sinuses that help maintain normal physiological blood flow. While this feature holds clear benefits when the valve is implanted in the high-pressure aorta, it may prove even more advantageous in the lower-pressure pulmonary circulation. Under these conditions, proper blood flow around the valve helps clean its surfaces, potentially extending its functional lifespan even further.
The Clinical Challenge: Congenital Heart Disease and Repeat Surgeries
To appreciate the significance of this heart valve innovation, it is essential to understand the clinical context in which it was applied. The two patients who received the new graft—János Hadabás and Attila János Szikora—were both born with congenital heart defects and had already undergone multiple heart surgeries before requiring this latest intervention.
The Ross Procedure and Its Long-Term Limitations
Both patients had previously undergone a surgical approach known as the Ross procedure, in which the patient’s own pulmonary valve is transferred to replace a diseased aortic valve. The pulmonary valve position is then reconstructed using a pulmonary homograft—donor tissue transplanted from another person. While this approach offers advantages for younger patients, it creates a long-term challenge: over time, the transplanted pulmonary valve in the aortic position can become dilated, particularly given the high-pressure environment of the systemic circulation.
In both János’s and Attila’s cases, their original pulmonary valves, now functioning in the aortic position, had gradually dilated over the years. This dilation affected not only the valve but also the ascending aorta itself, meaning that replacing the valve alone would have been insufficient. Both the valve and the affected section of the aorta required replacement—a complex scenario that the new preassembled vascular graft was uniquely positioned to address.
The Cumulative Risk of Repeat Surgeries
Dr. Gábor Bari, head of the Department of Cardiac Surgery at the University of Szeged, emphasized a critical consideration in treating congenital heart disease patients: every additional heart surgery significantly increases the risk of complications. Because many of these patients undergo their first operation in childhood, they often require multiple procedures throughout their lives. Each repeat surgery involves reopening the chest, which carries progressively greater risks of adhesions, bleeding, and other complications.
“We have a responsibility to reduce the number of these operations whenever possible,” Dr. Bari stated. “The best way to achieve that is by using the most durable and advanced heart valves available.” For patients like János and Attila, the new graft offers the possibility of postponing the need for another valve replacement for up to 20 years—a substantial improvement over conventional alternatives.
Submit your application today to explore specialized cardiac surgery programs that integrate the latest innovations in heart valve technology.
A Novel Application: Adapting Technology for a Different Indication
Perhaps the most remarkable aspect of the University of Szeged’s achievement is not the technology itself but how it was applied. The vascular graft containing the biological heart valve was originally developed and approved for complete replacement of the ascending aorta—the first section of the body’s main artery, which operates under high systemic pressure.
From Aortic to Pulmonary Application
The University of Szeged team proposed using this device in the pulmonary circulation—a much lower-pressure system—for which it was not originally intended. This required not only clinical innovation but also special regulatory authorization from Hungary’s National Center for Public Health and Pharmacy (NNGYK). The authorization was granted based on the team’s scientifically supported clinical rationale, reinforced by the successful outcome of the initial procedure performed in the United States.
While the aortic and pulmonary valves share similar embryological development and anatomical structure, they differ significantly in the pressures they must withstand. The aortic valve functions under high systemic pressure, while the pulmonary valve operates in a low-pressure environment. The University of Szeged team recognized that a device designed to endure high-pressure conditions would likely perform exceptionally well in the less demanding pulmonary circulation—potentially with even greater longevity.
Accelerating Regulatory Approval
The timeline from device launch to clinical application in Hungary was remarkably short. Just 10 months after the manufacturer introduced the valved vascular graft, the University of Szeged team completed the scientific and clinical groundwork required to obtain regulatory approval and funding for the high-cost device. This rapid translation from innovation to patient benefit reflects both the team’s expertise and the university’s institutional commitment to advancing clinical practice.
Have questions about innovative cardiac procedures or the regulatory pathways for new medical devices? Write to us!
Patient Outcomes and Early Recovery
The early clinical results have been encouraging. Both patients reported significant improvement shortly after surgery. Attila János Szikora, who had begun experiencing symptoms before the operation—including bluish discoloration of his hands and feet—reported that these symptoms had completely disappeared following the procedure. János Hadabás, who learned about the innovative device only the day before his scheduled surgery, noted that the prospect of a shorter operation and more durable heart valve made the decision straightforward.
“People born with congenital heart disease often have to undergo multiple heart surgeries throughout their lives,” János observed. “If innovations like this can reduce the number of those operations, that is an enormous benefit.”
Both patients were transferred to cardiac rehabilitation shortly after their procedures, with expectations for full recovery. Dr. Bari expressed confidence in the long-term durability of the device, noting that clinical studies indicate it can remain functional for up to 25 years even in high-pressure circulatory systems. In the lower-pressure pulmonary circulation, its lifespan may prove even longer, although long-term clinical evidence is still being gathered.
The Broader Context: Cardiac Surgery Innovation at the University of Szeged
This heart valve innovation represents one component of a broader strategic vision for cardiovascular care at the University of Szeged. Since his appointment as head of the Department of Cardiac Surgery in November 2024, Dr. Gábor Bari has identified innovation as a central priority, spanning multiple areas: modernizing perioperative care, advancing surgical techniques, and introducing cutting-edge medical technologies into everyday clinical practice.
Integration with the Cardiology Center
The cardiac surgery department’s innovation efforts align closely with the vision of Prof. Dr. Tamás Szili-Török, Director of the University of Szeged’s Cardiology Center. Under his leadership, the Center has established specialized departments, divisions, and multidisciplinary teams that provide comprehensive expertise across cardiovascular care. This includes dedicated programs in sports cardiology, cardio-oncology, cardio-obstetrics, and a heart–brain team that addresses the intersection of cardiovascular and neurological conditions.
The Shift Toward Biological Valves
The University of Szeged’s adoption of advanced biological heart valves reflects a clear international trend in cardiac surgery. Historically, patients around age 50 were more likely to receive mechanical heart valves, which are generally durable enough to last a lifetime but require lifelong anticoagulant therapy—increasing the risk of bleeding and stroke. Recent advances in biological valve technology, however, have transformed this calculus. Today’s biological prostheses can function for 15 to 20 years without significant deterioration, and in some cases up to 25 years, making them increasingly viable options for younger patients.
The Department of Cardiac Surgery has consistently selected prosthetic heart valves from the world’s leading manufacturers, ensuring that patients from its catchment area of approximately 1.2 million people have access to the highest-quality options available.
Future Directions: Minimally Invasive and Robotic Surgery
Looking ahead, the University of Szeged is steadily expanding its use of minimally invasive endoscopic procedures, with the long-term goal of establishing a robotic cardiac surgery program. This evolution reflects a global trend in which cardiac surgery has moved away from procedures requiring large chest incisions toward approaches that reduce patient trauma and accelerate recovery.
Explore our related articles for further reading on advances in minimally invasive cardiac surgery and biological heart valve technology.
Implications for the Future of Cardiac Surgery
The University of Szeged’s experience with this heart valve innovation offers several important lessons for the broader cardiac surgery community. First, it demonstrates that significant clinical advances can occur not only through the development of entirely new technologies but also through the creative adaptation of existing devices for new applications. The team’s success in using an aortic graft in the pulmonary circulation shows how anatomical knowledge and clinical experience can expand the utility of medical innovations.
Second, the rapid regulatory approval process—completed in just 10 months—illustrates how strong scientific rationale and institutional support can accelerate the pathway from innovation to patient benefit. For healthcare systems seeking to monitor and adopt emerging technologies more effectively, this model offers a compelling case study.
Third, the focus on reducing repeat surgeries for congenital heart disease patients addresses a genuine unmet need. As survival rates for congenital heart disease continue to improve, the population of adults living with repaired hearts continues to grow. Developing strategies to minimize the number of lifetime surgeries for these patients represents an important priority for the field.
The University of Szeged’s achievement positions Hungary as a notable contributor to European cardiac surgery innovation. As Dr. Bari noted, the university’s institutional commitment to rapidly introducing innovative surgical techniques and advanced medical technologies into clinical practice creates an environment where promising developments can reach patients within a remarkably short time. This case serves as an outstanding example of that approach—and suggests that further surgical innovations from this institution are likely to follow.
